Dr. Rahul Kushwah reports

PREDICTMEDIX AI REBRANDS AS QSCREEN AI INC., (QAI) HARNESSING QUANTUM-AI SYNERGY FOR HEALTH SCREENING

Further to QScreen AI Inc.'s news releases of Jan. 12, 2026, the company has completed its name change to QScreen AI Inc.

As a result of the name change the company's common shares are expected to start trading under at the opening of trading on the Canadian Securities Exchange on or about Jan. 27, 2026. The company's new trading symbol will be CSE: QAI.

The articles of the company provide the directors with the authority to change the name of the company by way of directors' resolutions without consent of the shareholders. As a result of the name change, there has been no change to the company's share capital, business operations, management and strategic direction. The new Cusip is 746960103 and the new ISIN number is CA7469601032.

No action will be required by existing shareholders as a result of the name change and share certificates currently representing common shares of the company will not be affected or require exchange.

Evolution to QScreen AI Inc.

The move to QScreen AI reflects how the company has evolved: both technologically and strategically. What began as an AI-driven health screening company has developed into a broader screening and decision-intelligence platform, built to operate in complex, real-world environments where speed, accuracy and signal quality matter. Over time, the earlier name became increasingly narrow relative to what the company now delivers.

As part of this evolution, the company has been advancing beyond traditional AI architectures. Its platform incorporates quantum-inspired and advanced computational techniques alongside classical machine learning to improve how large, high-dimensional data sets are processed, analyzed and translated into actionable insights.

These approaches are designed to enhance:

• Detection of weak or non-linear signals;
• Performance in data-dense, time-sensitive environments;
• Scalability across enterprise and government deployments.

The QScreen AI name better reflects this reality, a company focused on screening, inference and decision support, rather than a single application or vertical.

The company continues to advance its technology road map with a clear focus on commercializing advanced, quantum-enhanced AI capabilities into practical, deployable systems. Management believes this transition is well-timed, delivering stronger alignment between the company's technology, its market positioning, and its growing recognition among partners and investors. With this transition, QScreen AI enters its next phase of growth, focused on scaling and commercializing advanced AI screening technologies, including those leveraging quantum-inspired computation across health care, safety and other high-value adjacent markets. To support this evolution, the company is onboarding key strategic individuals with deep industry expertise to drive global commercialization and accelerate market penetration of its quantum-AI technologies.

About QScreenAI Inc.

QScreen AI is an emerging provider of rapid health screening and remote patient care solutions globally. The company's Smarthealth AI stations are powered by a proprietary artificial intelligence (AI) and use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue or various mental illnesses. QScreen AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes.

We seek Safe Harbor.